Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Consensus Recommendation of “Reduce” by Brokerages

Integra LifeSciences Holdings Co. (NASDAQ:IART) has been assigned an average rating of “Reduce” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $23.00.

A number of equities analysts have recently issued reports on IART shares. Morgan Stanley initiated coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price for the company. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th.

Integra LifeSciences Trading Up 4.4 %

Shares of Integra LifeSciences stock opened at $22.05 on Thursday. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $44.91. The firm has a market capitalization of $1.70 billion, a PE ratio of -244.97, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. The company’s fifty day moving average price is $23.68 and its two-hundred day moving average price is $21.81.

Insider Transactions at Integra LifeSciences

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the sale, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Sachem Head Capital Management LP bought a new stake in shares of Integra LifeSciences during the third quarter worth $44,153,000. Soleus Capital Management L.P. bought a new position in Integra LifeSciences in the fourth quarter valued at about $28,940,000. Paradigm Capital Management Inc. NY increased its position in Integra LifeSciences by 170.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 1,431,100 shares of the life sciences company’s stock worth $32,457,000 after purchasing an additional 901,600 shares during the period. Lord Abbett & CO. LLC lifted its position in Integra LifeSciences by 86.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,332,031 shares of the life sciences company’s stock valued at $30,210,000 after purchasing an additional 618,773 shares during the period. Finally, Glenmede Trust Co. NA lifted its position in Integra LifeSciences by 125.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 727,781 shares of the life sciences company’s stock valued at $13,224,000 after purchasing an additional 405,624 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.